Tango Therapeutics, Inc. (TNGX) - Dilution Analysis

10-Q filing | 134.6M shares outstanding

10-Q filing | 110.5M shares outstanding

10-Q filing | 110.3M shares outstanding

S-3 filing: Tango Therapeutics, Inc. files an S-3 to offer and sell up to $400,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units, in any combination. They also file an prospectus supplement to offer common stock through Jefferies LLC for up to $100,000,000.

10-K filing | 109.2M shares outstanding

10-Q filing | 108.5M shares outstanding

10-Q filing | 108.3M shares outstanding

10-Q filing | 108.2M shares outstanding

10-K filing | 106.7M shares outstanding

10-Q filing | 97.0M shares outstanding

S-3 filing: This prospectus relates to the proposed resale or other disposition from time to time of up to (i) 13,196,671 shares of our common stock and (ii) 2,340,579 shares of our common stock issuable upon the exercise of pre-funded warrants, or collectively the Shares, by the selling stockholders identified in this prospectus.

10-Q filing | 88.4M shares outstanding

10-Q filing | 88.2M shares outstanding

10-K filing | 87.8M shares outstanding

10-Q filing | 87.9M shares outstanding

POS AM filing: This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus, or the Selling Securityholders, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of (i) up to 18,610,000 shares of our common stock that were issued to certain investors, or collectively, the PIPE Investors, in a private placement in connection with the closing of the Business Combination (as defined below) and (ii) up to 49,424,602 shares of our common stock that were issued to certain former shareholders of Tango Therapeutics Sub, Inc. at the closing of the Business Combination.

S-3 filing: Tango Therapeutics, Inc. is offering common stock, preferred stock, and debt securities up to an aggregate amount of $400,000,000 and is offering common stock through Jefferies LLC up to $100,000,000.

10-Q filing | 87.8M shares outstanding

10-Q filing | 87.9M shares outstanding

POS AM filing: This POS AM filing registers up to 68,175,412 shares of common stock for resale by selling securityholders, including shares issued in a private placement and to former shareholders of Tango Therapeutics Sub, Inc. at the closing of the Business Combination.

10-K filing | 87.7M shares outstanding

10-Q filing | 87.5M shares outstanding

S-1 filing: This S-1 filing registers up to 68,175,412 shares of common stock for resale by selling securityholders, consisting of shares issued in a private placement and to former shareholders of Tango Therapeutics Sub, Inc. in connection with a business combination.

10-Q filing | 21.4M shares outstanding

10-Q filing | 21.4M shares outstanding

8-K filing: BCTG Acquisition Corp. entered into a merger agreement with Tango Therapeutics, Inc., where BCTG will acquire all outstanding shares of Tango common stock for $550,000,000, comprising 55,000,000 shares of BCTG common stock at $10.00 per share, and also entered into subscription agreements to issue 18,610,000 shares of BCTG common stock at $10.00 per share for a total of $186,100,000.00. ($186.1M proceeds)

10-K filing | 21.4M shares outstanding

10-Q filing | 21.4M shares outstanding

8-K filing: BCTG Acquisition Corp. consummated its initial public offering of 16,675,000 shares of common stock at $10.00 per share, generating gross proceeds of $166,750,000, and simultaneously consummated a private placement with BCTG Holdings, LLC, for 533,500 shares of common stock at $10.00 per share, generating total proceeds of $5,335,000. ($172.09M proceeds)

8-K filing: BCTG Acquisition Corp. consummated its initial public offering of 16,675,000 shares of common stock at $10.00 per share, generating gross proceeds of $166,750,000, and also completed a private placement with the Sponsor of 533,500 shares of common stock at $10.00 per share, generating total proceeds of $5,335,000. ($172.09M proceeds)

S-1/A filing: This S-1/A filing registers shares of common stock for an initial public offering and a concurrent private placement to the sponsor.

S-1 filing: BCTG Acquisition Corp. is offering 12,500,000 shares of common stock in an initial public offering at a price of $10.00 per share.